POC Plan
Integration Plan: 4-Month MAIA-QED Cognitive-Quantum Architecture POC with Value to AbbVie/AbbVie Ventures
March 25, 2025 - July 24, 2025
Prepared for AbbVie Ventures
Introduction
This revised integration plan extends the MAIA-QED (Quantum Enhanced Diagnostics) Cognitive-Quantum Architecture Proof of Concept (POC) to a 4-month timeline (March 25, 2025, to July 24, 2025) and incorporates extrapolative pointers on the value delivered to AbbVie and AbbVie Ventures. The POC builds on the RetinalGAN-PGAN-MAIA codebase, integrating the Perceptual Decomposition Engine, QAOA optimization, and ESRGANx4 reconstruction components, leveraging datasets (OCTDL, Kermany, OCTID, RETOUCH), and aligning with AbbVie's priorities in eye care (AMD, DME, RVO), neuroscience (Alzheimer's biomarkers), and diagnostic innovation (telemedicine-ready cognitive distillation).
The plan includes funding requirements, milestones, and success metrics, with a focus on delivering tangible value to AbbVie through enhanced diagnostics, therapeutic insights, and strategic positioning through patent-pending quantum-cognitive methods.
Core Management Team
The following executive leadership team will drive the POC implementation, strategic direction, and stakeholder engagement:
| Role | Responsibilities | Annual Compensation (SF Rate) |
|---|---|---|
| CEO |
| $275,000 |
| CTO |
| $250,000 |
| CMO (part-time) |
| $150,000 (0.5 FTE) |
| COO |
| $225,000 |
Total 4-month management compensation: $300,000 (prorated for POC period)
Funding Requirements
Total funding request: $2.4522 million over 4 months, allocated as follows:
| Category | Amount | Details |
|---|---|---|
| Personnel & Management (53.5%) | $1,893,930 |
|
| Computational Resources (18%) | $621,320 |
|
| IP Development & Filing (7%) | $250,000 |
|
| Dataset Access and Validation (8%) | $367,830 |
|
| Miscellaneous & Contingency (13.5%) | $472,610 |
|
| Total | $3,605,690 |
Note: While the total project cost is $3,605,690, the funding request from AbbVie Ventures remains at $2,452,200 (68% of total). The remaining $1,153,490 will be secured from additional sources.
Datasets and AbbVie Alignment
OCTDL (2,064 images)
Primary training dataset covering AMD, DME, RVO, ERM, RAO, VID. Aligns with AbbVie's eye care priorities.
Kermany et al. (thousands of images)
Validation dataset focusing on CNV, DME, Drusen, and Normal cases. Supports cross-device generalization.
OCTID (500+ images)
Specialized testing dataset with segmentation for AMD, DR, MH, CSR. Enhances fine-grained analysis.
RETOUCH (~300 images)
Added for fluid segmentation (DME, CNV), enhancing clinical relevance and alignment with AbbVie's therapeutic focus.
These datasets align with AbbVie's focus on eye care (e.g., Ozurdex for DME/RVO, AMD R&D) and neuroscience (Alzheimer's biomarkers via retinal imaging), supporting QED's cognitive-quantum innovation for telemedicine.
IP Strategy and Development
A robust IP portfolio is critical to protect QED's innovations and create defensible market space. Our IP strategy includes:
Patent Portfolio Development
- Patent 1: "Quantum-Cognitive Encoder for Medical Imaging" (Core technology)
- Patent 2: "Perceptual Decomposition Engine for Diagnostic Relevance" (Semantic layer extraction)
- Patent 3: "Therapeutic Response Fingerprinting in Latent Space" (DME/RVO monitoring)
IP Filing Timeline
- Month 1: Prior art search and patentability assessment
- Month 2: Provisional patent applications for all three inventions
- Month 4: PCT application preparation for international protection
- Post-POC: Full utility patent filings with expanded claims
Our IP strategy creates a multi-layered defense against competitors:
- Core patents on the quantum-cognitive architecture create fundamental barriers to entry
- Application-specific patents (e.g., therapeutic response fingerprinting) protect high-value use cases
- Strategic PCT filings enable global protection in key markets (US, EU, Japan, China)
- Trade secrets will protect implementation details not disclosed in patents
The IP budget includes attorney fees, filing costs, and strategic consulting to maximize protection while avoiding WaveOne/H.266 litigation risks.
Roadmap: Phased Implementation Plan
The roadmap spans 4 months, with milestones, deliverables, and success metrics for each phase. The timeline adjusts for deeper development and validation, targeting a higher VMAF metric (≥95) for quality assurance.
Phase 0: Core Infrastructure Setup (March 25–April 7, 2025)
Objective: Establish a stable foundation, verify the current codebase, and prepare for dataset integration.
Key Milestones:
- March 31: Environment setup completed with MI300X clusters
- April 7: Synthetic data pipeline tested, ≥90% success rate
Proof Points:
- Do: Execute base RetinalGAN with synthetic data
- Prove: Environment stability (PyTorch + CUDA working)
- Metric: ≥90% synthetic image generation success rate
Funding Allocation: $150,000 (initial setup, personnel, compute resources)
Phase 1: Dataset Integration and Perceptual Decomposition (April 8–May 5, 2025)
Objective: Integrate multiple datasets, implementing the Perceptual Decomposition Engine for semantic, motion, and fractal-edge layer extraction.
Key Milestones:
- April 14: OCTDL preprocessing completed
- April 21: YOLOv8+CLIP semantic layer extraction implemented
- April 28: Sparse RAFT motion layer integration
- May 5: Fractal-edge layer extraction completed
Proof Points:
- Do: Extract semantic, motion, and fractal-edge layers from OCT data
- Prove: Accurate layer extraction for AMD, DME, CNV, and fluid regions
- Metric: Dice score ≥0.87 vs. clinical annotations
Funding Allocation: $600,000 (dataset licensing, preprocessing infrastructure, personnel)
Phase 2: QAOA Optimization and Cognitive Distillation (May 6–June 9, 2025)
Objective: Implement QAOA optimization for diagnostic relevance and cognitive distillation with Xanadu and Azure Quantum.
Key Milestones:
- May 19: QAOA implementation for diagnostic relevance optimization
- June 2: Cognitive distillation pipeline achieving 92% data reduction
- June 9: structure.maia + key.maia file format finalized
Proof Points:
- Do: Implement QAOA optimization and cognitive distillation
- Prove: Faster feature extraction and significant data reduction
- Metric: 35% reduction in feature extraction time, 92% data reduction (10GB to 20MB)
Funding Allocation: $800,000 (compute resources, quantum access, personnel)
Phase 3: ESRGANx4 Reconstruction and AbbVie Enhancements (June 10–July 7, 2025)
Objective: Implement ESRGANx4 reconstruction and add AbbVie-specific enhancements.
Key Tasks:
- Implement ESRGANx4 for 4K perspective reconstruction with VMAF ≥95
- Integrate Azure Quantum Storage and Xanadu validation
- Add AbbVie-specific enhancements:
- Therapeutic response fingerprints in latent space
- Potential Alzheimer's biomarker detection in AMD images
- Balanced dataset training to mitigate bias
Key Milestones:
- June 23: ESRGANx4 reconstruction implemented, VMAF ≥95 achieved
- July 7: Azure/Xanadu integrations and AbbVie enhancements implemented
Proof Points:
- Do: Reconstruct 4K perspectives from cognitively distilled data
- Prove: Diagnostic fidelity and potential biomarker detection
- Metric: VMAF ≥95 at 4K reconstruction, potential Alzheimer's biomarker detection capabilities
Funding Allocation: $600,000 (compute resources, personnel, validation studies)
Phase 4: Clinical Validation and Demo Preparation (July 8–July 24, 2025)
Objective: Finalize the end-to-end cognitive-quantum pipeline, conduct clinical validation, and prepare a demo for AbbVie Ventures.
Key Milestones:
- July 16: Full pipeline tested with AbbVie DME/RVO patient data, 95% diagnostic agreement achieved
- July 21: Clinical validation completed with AbbVie, Mayo Clinic and MSU
- July 24: Demo presentation ready with FDA 510(k) pre-submission plan
Proof Points:
- Do: End-to-end OCT → Perceptual Decomposition → QAOA → Cognitive Distillation → ESRGANx4 workflow
- Prove: Clinical workflow viability and patent-pending quantum-cognitive methods
- Metric: 95% diagnostic agreement with gold standard, VMAF ≥95, 92% data reduction
Funding Allocation: $302,200 (clinical validation, personnel, travel for demo)
Capabilities and Proof Points After Implementation
What You Can Do by July 24, 2025
- Phase 0 (April 7): Execute the base pipeline with synthetic data on MI300X clusters
- Phase 1 (May 5): Extract semantic, motion, and fractal-edge layers from OCT data
- Phase 2 (June 9): Achieve 92% data reduction (10GB to 20MB) with QAOA optimization
- Phase 3 (July 7): Reconstruct 4K perspectives with ESRGANx4 enhancement
- Phase 4 (July 24): Demonstrate end-to-end cognitive-quantum workflow with clinical validation
What You Can Prove
Technical Readiness
- 92% data reduction (10GB to 20MB)
- 35% faster feature extraction with QAOA
- 4K perspective reconstruction with VMAF ≥95
Diagnostic Accuracy
- 95% diagnostic agreement for AMD, DME, RVO, CNV, Drusen
- Dice score ≥0.90 for CNV/DME segmentation
- Potential Alzheimer's biomarker detection capabilities
AbbVie-Specific Value
- Therapeutic response fingerprints for DME (post-Ozurdex)
- Patent-pending quantum-cognitive methods
- FDA 510(k) pre-submission plan
Demo Deliverables
- End-to-end cognitive-quantum pipeline
- Clinical validation report with Mayo Clinic and MSU
- Presentation highlighting DME, RVO, AMD diagnostics
Value Delivered to AbbVie/AbbVie Ventures from the POC
Enhanced Diagnostic Capabilities for Eye Care
Value: QED enables cognitive distillation of OCT data with VMAF ≥95, allowing AbbVie to implement telemedicine solutions for remote DME and RVO monitoring, directly supporting Ozurdex patients. This reduces data storage costs by up to 92% (e.g., from 10GB to 20MB per patient dataset) and enables faster transmission over low-bandwidth networks, improving access in underserved regions.
Extrapolation: AbbVie can leverage QED to enhance clinical trial efficiency for AMD therapies, reducing imaging data management costs by an estimated $1-2 million annually across trials, while ensuring diagnostic accuracy (95% agreement) for patient stratification and monitoring.
Accelerated Neuroscience R&D with Alzheimer's Biomarkers
Value: The POC's quantum-encoded features offer potential for Alzheimer's biomarker detection in AMD patients, providing AbbVie with a non-invasive retinal imaging tool to identify early Alzheimer's risk. This aligns with their $8.7 billion Cerevel acquisition, enhancing their neuroscience pipeline.
Extrapolation: AbbVie can integrate QED into Alzheimer's clinical trials, potentially identifying at-risk patients earlier than current methods (e.g., CSF biomarkers), saving $5-10 million in trial costs by reducing patient recruitment timelines and improving cohort selection accuracy.
Therapeutic Response Insights for DME and RVO
Value: QED's therapeutic response fingerprints track DME fluid changes post-Ozurdex with high precision (Dice score ≥0.90), offering AbbVie real-time insights into treatment efficacy. This supports personalized medicine approaches, optimizing Ozurdex dosing regimens.
Extrapolation: AbbVie can use QED to develop predictive models for Ozurdex response, potentially increasing treatment success rates by 10-15% (e.g., reducing DME recurrence), which could translate to $50-100 million in additional annual revenue from improved patient outcomes and market share in DME therapies.
Strategic Positioning in Diagnostic Innovation
Value: QED's integration of quantum and cognitive technologies positions AbbVie as a leader in next-generation diagnostics, aligning with their interest in transformative tech. The POC's patent-pending quantum-cognitive methods create defensible market space, avoiding WaveOne/H.266 litigation risks.
Extrapolation: By adopting QED, AbbVie Ventures can position AbbVie as a pioneer in quantum-enhanced diagnostics, potentially attracting $100-200 million in additional investment or partnerships from tech-focused healthcare funds, while gaining a competitive edge over rivals like Roche in retinal diagnostics.
Pathway to Regulatory and Commercial Success
Value: The POC's clinical validation (95% diagnostic agreement) and focus on VMAF ≥95 provide a strong foundation for FDA 510(k) pre-submission, de-risking QED's path to market. This aligns with AbbVie Ventures' goal of supporting portfolio companies through clinical stages.
Extrapolation: QED's validated cognitive-quantum capabilities could accelerate FDA clearance by 6-12 months, enabling AbbVie to launch a telemedicine platform for retinal care by 2027, potentially capturing a $500 million market segment in remote diagnostics for AMD and DME patients.
Project Timeline
| Phase | Start Date | End Date | Duration |
|---|---|---|---|
| Phase 0: Core Infrastructure Setup | March 25, 2025 | April 7, 2025 | 14 days |
| Phase 1: Perceptual Decomposition | April 8, 2025 | May 5, 2025 | 28 days |
| Phase 2: QAOA Optimization | May 6, 2025 | June 9, 2025 | 35 days |
| Phase 3: ESRGANx4 Reconstruction | June 10, 2025 | July 7, 2025 | 28 days |
| Phase 4: Clinical Validation | July 8, 2025 | July 24, 2025 | 17 days |
Next Steps: Transition to Act Mode
Proceed to Act Mode
Begin Phase 0 implementation, focusing on MI300X cluster setup and synthetic data testing, as outlined in the detailed plan.
Further Refinement
- Adjust success metrics (e.g., target VMAF 96 for even higher quality)
- Expand potential Alzheimer's biomarker focus with Mayo Clinic partnership
- Initiate FDA 510(k) pre-submission meetings
Value to AbbVie Ventures in Next Steps
- Act Mode: Immediate progress demonstrates execution capability, building trust in the team's ability to deliver, potentially increasing AbbVie Ventures' confidence to invest $2-3 million in a seed round.
- Refinement: Higher VMAF or deeper biomarker focus could position QED as a premium diagnostic tool, justifying a higher valuation (e.g., $10-15 million post-POC) for AbbVie Ventures' investment.
- Validation Expansion: Mayo Clinic partnership could attract co-investors (e.g., tech-focused VCs), reducing AbbVie Ventures' risk and enabling a $5-7 million syndicate round.